Use of a new antiepileptic drug or an old one as first drug for treatment of absence epilepsy

Epilepsia

Volumn 50, Issue SUPPL. 8, 2009, Pages 37-41

  Penovich, Patricia E ^a   James Willmore, L ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Absence seizures; Ethosuximide; Lamotrigine; Valproate

Indexed keywords

ANTICONVULSIVE AGENT; ETHOSUXIMIDE; ETIRACETAM; LAMOTRIGINE; PLACEBO; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ABDOMINAL PAIN; ABSENCE; ADD ON THERAPY; ADULT; ALOPECIA; ANOREXIA; APLASTIC ANEMIA; BEHAVIOR DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; DISEASE CONTROL; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FETUS MALFORMATION; FOCAL EPILEPSY; GASTROINTESTINAL SYMPTOM; GLAUCOMA; HEALTH CARE QUALITY; HEMATOLOGIC DISEASE; HEPATITIS; HUMAN; HYPERKINESIA; LIVER TOXICITY; NAUSEA; NEPHROLITHIASIS; OBSERVATIONAL STUDY; PANCREATITIS; PANCYTOPENIA; PARESTHESIA; PATIENT SAFETY; PRIORITY JOURNAL; RASH; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; STOMACH DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; THERAPY EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN;

ANTICONVULSANTS; DRUG MONITORING; EPILEPSY, ABSENCE; ETHOSUXIMIDE; HUMANS; TREATMENT OUTCOME; TRIAZINES; VALPROIC ACID;

EID: 68949212299     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2009.02234.x     Document Type: Review

References (34)

1. Arzimanoglou A, Kulak I, Bidaut-Mazel C, Baldy-Moulinier M 2001) Optimal use of lamotrigine in clinical practice: results of an open multicenter trial in refractory epilepsy. Rev Neurol (Paris) 157 : 525 536.
2. Asconape JJ, Penry JK, Dreifuss FE, Riela A, Mirza W 1993) Valproate-associated pancreatitis. Epilepsia 34 : 177 183.
3. Beran RG, Berkovic SF, Dunagan FM, Vajda J, Danta G, Black AB, Mackenzie R. (1998) Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy. Epilepsia 39 : 1329 1333.
4. Biton V, Montouris GD, Ritter F, Riviello JJ, Reife R, Lim P, Pledger G. (1999) A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurol 52 : 1330 1337.
5. Browne TR, Dreifuss FE, Dyken PR, Goode DR, Penry JK, Porter RJ, White PT, White BG. (1975) Ethosuximide in the treatment of absence (petit mal) epilepsy. Neurol 25 : 515 525.
6. Buoni S, Grosso S, Fois A 1999) Lamotrigine in typical absence epilepsy. Brain Dev 21 : 303 306.
7. Cavitt J, Privitera M 2004) Levetiracetam induces a rapid and sustained reduction of generalized spike-wave and clinical absence. Arch Neurol 61 : 1604 1607.
8. Coppola G, Auricchio G, Federico R, Carotenuto M, Pascotto A 2004a) Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia 45 : 1049 1053.
9. Coppola G, Licciardi F, Sciscio N, Russo F, Carotenuto M, Pascotto A 2004b) Lamotrigine as a first-line drug in childhood absence epilepsy: a clinical and neurophysiological study. Brain Dev 26 : 26 29.
10. Cross JH 2002) Topiramate monotherapy for childhood absence seizures: an open label pilot study. Seizure 11 : 406 410.
11. Cunningham MO, Jones RS 2000) The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increased spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology 39 : 2139 2146.
12. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB 1987) Valproic acid hepatic fatalities: a retrospective review. Neurol 37 : 379 385.
13. Eriksson A-S, Knutsson E, Nergardh A 2001) The effect of lamotrigine on epileptiform discharges in young patients with drug-resistant epilepsy. Epilepsia 42 : 230 236.
14. Farrell K, Connolly MB, Munn R, Peng S, MacWilliam LM 1997) Prospective, open-label, add-on study of lamotrigine in 56 children with intractable generalized epilepsy. Pediatr Neurol 16 : 201 205.
15. Ferrie CD, Robinson RO, Knott C, Panayiotopoulos CP 1995) Lamotrigine as an add-on drug in typical absence seizures. Acta Neurol Scand 91 : 200 202.
16. Frank LM, Enlow T, Holmes GL, Manasco P, Concannon S, Chen C, Womble G, Casale EJ. (1999) Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 40 : 973 979.
17. Goldensohn ES, Hardie J, Borea E 1962) Ethosuximide in the treatment of epilepsy. JAMA 180 : 840 842.
18. Iinuma K, Haginoya K 2004) Clinical efficacy of zonisamide in childhood epilepsy after long term treatment: a post marketing, multiinstitutional survey. Seizure 13S : S34 S39.
19. Kasteleijn-Nolst Trenité DG, Marescaux C, Stodieck S, Edelbroek PM, Oosting J. (1996) Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue levetiracetam. Epilepsy Res 25 : 225 230.
20. Kiorboe E, Paludan J, Trolle E, Overvad E 1964) Zarontin (ethosuximide) in the treatment of petit mal and related disorders. Epilepsia 5 : 83 89.
21. Krauss GL, Betts T, Abou-Khalil B, Gergey G, Yarrow H, Miller A 2003) Levetiracetam treatment of idiopathic generalised epilepsy. Seizure 12 : 617 620.
22. Kumar SP, Smith PE 2004) Levetiracetam as add-on therapy in generalised epilepsies. Seizure 13 : 475 477.
23. Lindhout D, Meinardi H 1984) Spina bifida and in utero exposure to valproate. Lancet 2 : 396.
24. Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW, NEAD Study Group 2009) Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Eng J Med 360 : 1597 1605.
25. Messenheimer JA, Ramsay RA, Willmore LJ, Leroy RF, Zielinski JJ, Mattson R, Pellock JM, Valakas AM, Womble G, Risner M. (1994) Lamotrigine therapy for partial seizures: a multicenter placebo- controlled, double-blind, crossover trial. Epilepsia 35 : 113 121.
26. Noachtar S, Andermann E, Meyvisch P, Andermann F, Gough WB, Schiemann-Delgado J N166 Levetiracetam Study Group 2008) Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurol 70 : 607 616.
27. Panayiotopoulos CP 2001) Treatment of typical absence seizures and related epileptic syndromes. Paediatr Drugs 3 : 379 404.
28. Sato S, White BG, Penry JK, Dreifuss FE, Sackellares JC, Kupferberg HJ 1982) Valproic acid versus ethosuximide in the treatment of absence seizures. Neurol 32 : 157 163.
29. Villarreal HJ, Wilder BJ, Willmore LJ, Bauman AW, Hammond EJ, Bruni J 1978) Effect of valproic acid on spike and wave discharges in patients with absence seizures. Neurol 28 : 886 891.
30. Wilfong A, Schultz R 2005) Zonisamide for absence seizures. Epilepsy Res 64 : 31 34.
31. Willmore LJ, Wilder BJ, Bruni J, Villarreal HJ 1978) Effect of valproic acid on hepatic function. Neurol 28 : 961 964.
32. Yagi K 2004) Overview of Japanese experience-controlled and uncontrolled trials. Seizure 13 (suppl 1 S11 S15.
33. Yamauchi T, Aikawa H 2004) Efficacy of zonisamide: our experience. Seizure 13 (suppl 1 S41 S48.
34. Zimmerman FT, Burgemeister BB 1958) A new drug for petit mal epilepsy. Neurol 8 : 769 775.